摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-methoxy-1,3-dimethyl-butylamine | 79090-59-8

中文名称
——
中文别名
——
英文名称
3-methoxy-1,3-dimethyl-butylamine
英文别名
4-Amino-2-methoxy-2-methyl-pentan;4-Methoxy-4-methylpentan-2-amine
3-methoxy-1,3-dimethyl-butylamine化学式
CAS
79090-59-8
化学式
C7H17NO
mdl
MFCD11199650
分子量
131.218
InChiKey
GGSAMCDSFWBGCU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.5
  • 重原子数:
    9
  • 可旋转键数:
    3
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    35.2
  • 氢给体数:
    1
  • 氢受体数:
    2

反应信息

  • 作为产物:
    描述:
    alkaline earth salt of/the/ methylsulfuric acid 在 甲醇sodium 作用下, 生成 3-methoxy-1,3-dimethyl-butylamine
    参考文献:
    名称:
    ALIPHATIC AMINES OF PHARMACOLOGIC INTEREST. I. 2-AMINO ALKANOLS AND THEIR DERIVATIVES2
    摘要:
    DOI:
    10.1021/jo01137a019
点击查看最新优质反应信息

文献信息

  • [EN] SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B<br/>[FR] SULFAMOYL-ARYLAMIDES ET LEUR UTILISATION EN TANT QUE MÉDICAMENTS POUR LE TRAITEMENT DE L'HÉPATITE B
    申请人:JANSSEN R & D IRELAND
    公开号:WO2014131847A1
    公开(公告)日:2014-09-04
    Inhibitors of HBV replication of Formula (I) including stereochemically isomeric forms, salts, hydrates and solvates thereof, wherein R1, R2, R3 and R4 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.
    公式(I)的HBV复制抑制剂包括立体化学异构体形式、盐类、合物和溶剂合物,其中R1、R2、R3和R4的含义如本文所定义。本发明还涉及制备所述化合物的过程、含有它们的药物组合物以及它们在HBV治疗中单独或与其他HBV抑制剂结合使用的用途。
  • Benzimidazole derivatives
    申请人:——
    公开号:US20040044056A1
    公开(公告)日:2004-03-04
    This invention relates to the compounds represented by a general formula [I]: 1 [in which A 1 and A 2 represent optionally fluorine-substituted methine or the like; B represents halogen, cyano, lower alkyl or the like; D represents optionally substituted heterocyclic group or the like; and G represents C 3 -C 20 aliphatic group such as alicyclic group]. These compounds inhibit nociceptin activities due to their high affinity to nociceptin receptor, and are useful as analgesic, antiobestic, corebral function improver, drugs for treatment of alzheimer's disease and dementia, remedies for schizophrenia and neurodegenerative diseases, antidepressant, remedies for diabetes insipidus, polyuria, hypotension and so on.
    本发明涉及由一般式[I]表示的化合物:1[其中,A1和A2表示选择性代甲基或类似物;B表示卤素,基,低碳烷基或类似物;D表示选择性取代的杂环基团或类似物;G表示C3-C20脂肪族基团,例如脂环族基团]。这些化合物由于对痛觉受体具有高亲和力而抑制了痛觉肽活性,并且可用作镇痛剂,抗肥胖剂,脑功能改善剂,治疗阿尔茨海默病和痴呆症的药物,治疗精神分裂症和神经退行性疾病的药物,抗抑郁剂,治疗尿崩症,多尿症,低血压等的药物。
  • SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B
    申请人:JANSSEN SCIENCES IRELAND UC
    公开号:US20160002155A1
    公开(公告)日:2016-01-07
    Inhibitors of HBV replication of Formula (I) including stereochemically isomeric forms, salts, hydrates and solvates thereof, wherein R 1 , R 2 , R 3 and R 4 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.
    公式(I)中HBV复制抑制剂包括立体化学同分异构体形式,盐、合物和溶剂化物,其中R1、R2、R3和R4的含义如此处所定义。本发明还涉及制备该化合物的过程,含有它们的制药组合物及其在HBV治疗中的单独使用或与其他HBV抑制剂联合使用。
  • BENZIMIDAZOLE DERIVATIVES
    申请人:BANYU PHARMACEUTICAL CO., LTD.
    公开号:EP1342717A1
    公开(公告)日:2003-09-10
    This invention relates to the compounds represented by a general formula [I]:    [in which A1 and A2 represent optionally fluorine-substituted methine or the like; B represents halogen, cyano, lower alkyl or the like; D represents optionally substituted heterocyclic group or the like; and G represents C3-C20 aliphatic group such as alicyclic group]. These compounds inhibit nociceptin activities due to their high affinity to nociceptin receptor, and are useful as analgesic, antiobestic, corebral function improver, drugs for treatment of alzheimer's disease and dementia, remedies for schizophrenia and neurodegenerative diseases, antidepressant, remedies for diabetes insipidus, polyuria, hypotension and so on.
    本发明涉及通式[I]所代表的化合物: [其中 A1 和 A2 代表任选取代的甲基或类似物;B 代表卤素、基、低级烷基或类似物;D 代表任选取代的杂环基团或类似物;G 代表 C3-C20 脂肪族基团,例如脂环族基团]。这些化合物由于与痛觉素受体的高亲和力而抑制痛觉素的活性,可用作镇痛剂、抗镇静剂、改善大脑核心功能的药物、治疗老年痴呆症和痴呆症的药物、治疗精神分裂症和神经退行性疾病的药物、抗抑郁剂、治疗糖尿病、多尿、低血压等。
  • Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B
    申请人:Janssen Sciences Ireland UC
    公开号:US10125094B2
    公开(公告)日:2018-11-13
    Inhibitors of HBV replication of Formula (I) including stereochemically isomeric forms, salts, hydrates and solvates thereof, wherein R1, R2, R3 and R4 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.
    式 (I) 的 HBV 复制抑制剂 包括其立体异构体、盐、合物和溶液,其中 R1、R2、R3 和 R4 的含义如本文所定义。 本发明还涉及制备所述化合物的工艺、含有这些化合物的药物组合物以及它们在 HBV 治疗中单独或与其他 HBV 抑制剂联合使用的情况。
查看更多